Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4223676 | 0.84 | LOXL2 (0.59) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL44366 | 0.81 | POLB (0.76) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL8087428 | 0.81 | POLB (0.76) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL8094050 | 0.81 | POLB (0.76) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL4521415 | 0.81 | PYCR1 (0.57) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL398128 | 0.81 | GAA (0.59) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL4230681 | 0.81 | LOXL2 (0.55) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL3633599 | 0.81 | LOXL2 (0.55) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL12415808 | 0.81 | PYCR1 (0.57) | LOXL2POLBTSHRIDO1CYP2C19 | |
| SCHEMBL1528870 | 0.79 | TSHR (0.60) | LOXL2POLBTSHRIDO1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-3738591-A2 | NOVEL ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-18 | — | — | EP | claimed |
| WO-2018229261-A1 | COMBINATION MEDICAMENT COMPRISING A PRODRUG AND INHALABLE CATALYST | ETH Zürich (CH) | 2018-12-20 | — | — | WO | claimed |
| CN-108310000-A | Treat malaria, the method for tuberculosis and MAC diseases | 森普拉制药公司 | 2018-07-24 | — | — | CN | claimed |
| US-9669046-B2 | Biodefenses using triazole-containing macrolides | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-2475253-B1 | METHODS FOR TREATING MALARIA, TUBERCULOSIS AND MAC DISEASES | CEMPRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160280718-A1 | NOVEL ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-09-29 | — | — | US | claimed |
| CN-103601641-B | Glaucocalyxin A derivative and in the application of preparing in antineoplastic | ARMY MEDICAL UNIV. NO.2, CHINESE PLA (CN) | 2016-05-04 | — | — | CN | claimed |
| US-20160082028-A1 | BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES | TETARD, INC. | 2016-03-24 | — | — | US | claimed |
| EP-2772254-A2 | Novel Antibacterial Agents | Optimer Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | claimed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | claimed |
| US-5656753-A | 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1997-08-12 | — | — | US | claimed |
| WO-1996029088-A1 | NOVEL PIPERAZINE DERIVATIVES AS TYPE IL-1 RECEPTOR ANTAGONISTS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-09-26 | — | — | WO | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4401594-A | PROTEOLYTIC ENZYME INHIBIJTORS; CARDIOVASCULAR AND MUSCULAR DISORDERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | claimed |
| US-4401660-A | TYLOSINS; VETERINARY MEDICINE; PASTEURELLA; ANIMAL GROWTH REGULATORS | ELI LILLY AND COMPANY (US) | 1983-08-30 | — | — | US | claimed |
| US-4396613-A | DEMYCINOSYLTYLOSIN, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | claimed |
| US-4159267-A | Novel silyl ester azetidine-2-sulfenate intermediates and process for preparing desacetoxycephalosporins | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280718-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, MRPL12, CTSA | LOXL2 3529/4885POLB 4318/4885TSHR 3235/4885 |
| US-20160082028-A1 | BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES | ABHD16A, ABHD12, BRDT | LOXL2 2808/4885POLB 2623/4885TSHR 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.